Cosmos Health Inc. (COSM)
USD 0.34
(-2.95%)
USD 0.34
(-2.95%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 26.18 Million USD | 90.35% |
| 2022 | 13.43 Million USD | 4.41% |
| 2021 | 12.86 Million USD | 140.62% |
| 2020 | 5.34 Million USD | 36.45% |
| 2019 | 3.91 Million USD | 7.73% |
| 2018 | 3.63 Million USD | -25.45% |
| 2017 | 4.87 Million USD | 507.15% |
| 2016 | 803.54 Thousand USD | 63.5% |
| 2015 | 491.45 Thousand USD | -6.08% |
| 2014 | 523.24 Thousand USD | -14.73% |
| 2013 | 613.65 Thousand USD | 134769.67% |
| 2012 | 455.00 USD | -99.73% |
| 2011 | 168.41 Thousand USD | -95.55% |
| 2010 | 3.78 Million USD | 82233.24% |
| 2009 | 4600.00 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 3.16 Million USD | -78.41% |
| 2024 Q2 | 2.95 Million USD | -6.74% |
| 2023 Q3 | 4.23 Million USD | 20.12% |
| 2023 FY | 25.56 Million USD | 90.35% |
| 2023 Q1 | 3.6 Million USD | -53.34% |
| 2023 Q2 | 3.52 Million USD | -2.35% |
| 2023 Q4 | 14.68 Million USD | 246.91% |
| 2022 Q1 | 1.64 Million USD | -52.29% |
| 2022 Q3 | 2.12 Million USD | 10.82% |
| 2022 Q4 | 7.73 Million USD | 263.39% |
| 2022 FY | 13.43 Million USD | 4.41% |
| 2022 Q2 | 1.92 Million USD | 16.4% |
| 2021 Q2 | 3.41 Million USD | 24.92% |
| 2021 Q3 | 3.26 Million USD | -4.49% |
| 2021 Q4 | 3.45 Million USD | 6.07% |
| 2021 FY | 12.86 Million USD | 140.62% |
| 2021 Q1 | 2.73 Million USD | 60.79% |
| 2020 Q1 | 967.6 Thousand USD | -19.83% |
| 2020 Q4 | 1.69 Million USD | 29.0% |
| 2020 Q3 | 1.31 Million USD | -3.27% |
| 2020 FY | 5.34 Million USD | 36.45% |
| 2020 Q2 | 1.36 Million USD | 40.74% |
| 2019 Q2 | 994.88 Thousand USD | 24.38% |
| 2019 Q4 | 1.2 Million USD | 31.72% |
| 2019 FY | 3.91 Million USD | 7.73% |
| 2019 Q1 | 799.9 Thousand USD | -40.49% |
| 2019 Q3 | 916.32 Thousand USD | -7.9% |
| 2018 Q2 | 781.11 Thousand USD | 2.84% |
| 2018 Q3 | 752.22 Thousand USD | -3.7% |
| 2018 Q4 | 1.34 Million USD | 78.69% |
| 2018 FY | 3.63 Million USD | -25.45% |
| 2018 Q1 | 759.54 Thousand USD | -68.93% |
| 2017 Q1 | 398.63 Thousand USD | 20.69% |
| 2017 FY | 4.87 Million USD | 507.15% |
| 2017 Q4 | 2.44 Million USD | 222.4% |
| 2017 Q3 | 758.36 Thousand USD | -40.6% |
| 2017 Q2 | 1.27 Million USD | 220.28% |
| 2016 Q2 | 168.63 Thousand USD | 31.04% |
| 2016 Q4 | 330.29 Thousand USD | 87.76% |
| 2016 Q3 | 175.91 Thousand USD | 4.32% |
| 2016 FY | 803.54 Thousand USD | 63.5% |
| 2016 Q1 | 128.69 Thousand USD | -42.09% |
| 2015 Q2 | 109.8 Thousand USD | 30.28% |
| 2015 Q1 | 84.28 Thousand USD | -5.38% |
| 2015 FY | 491.45 Thousand USD | -6.08% |
| 2015 Q4 | 222.21 Thousand USD | 195.69% |
| 2015 Q3 | 75.15 Thousand USD | -31.56% |
| 2014 Q2 | 168.26 Thousand USD | 129.95% |
| 2014 Q1 | 73.17 Thousand USD | 80.24% |
| 2014 Q3 | 192.73 Thousand USD | 14.55% |
| 2014 Q4 | 89.07 Thousand USD | -53.79% |
| 2014 FY | 523.24 Thousand USD | -14.73% |
| 2013 Q2 | 42 Thousand USD | -25.02% |
| 2013 FY | 613.65 Thousand USD | 134769.67% |
| 2013 Q1 | 56.02 Thousand USD | -50.26% |
| 2013 Q3 | 79.34 Thousand USD | 88.89% |
| 2013 Q4 | 40.59 Thousand USD | -48.83% |
| 2012 Q2 | 59.45 Thousand USD | 12.55% |
| 2012 Q1 | 52.82 Thousand USD | -3.59% |
| 2012 Q4 | 112.64 Thousand USD | -10.69% |
| 2012 Q3 | 126.12 Thousand USD | 112.12% |
| 2012 FY | 455.00 USD | -99.73% |
| 2011 Q3 | 159.78 Thousand USD | 161.04% |
| 2011 Q2 | 61.21 Thousand USD | -29.8% |
| 2011 Q4 | 54.79 Thousand USD | -65.71% |
| 2011 Q1 | 87.19 Thousand USD | 660.55% |
| 2011 FY | 168.41 Thousand USD | -95.55% |
| 2010 Q1 | 21.08 Thousand USD | 167.01% |
| 2010 FY | 3.78 Million USD | 82233.24% |
| 2010 Q2 | 3.71 Million USD | 17538.85% |
| 2010 Q3 | 8545.00 USD | -99.77% |
| 2010 Q4 | 11.46 Thousand USD | 34.16% |
| 2009 FY | 4600.00 USD | 0.0% |
| 2009 Q4 | 7897.00 USD | -79.76% |
| 2009 Q3 | 39.01 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -217.232% |
| Alpha Teknova, Inc. | 45.85 Million USD | 42.91% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 86.641% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | 41.631% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 83.556% |
| Journey Medical Corporation | 54.59 Million USD | 52.045% |
| Embecta Corp. | 528.4 Million USD | 95.045% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 90.371% |
| Dynavax Technologies Corporation | 219.14 Million USD | 88.053% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 95.563% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 91.978% |
| PainReform Ltd. | 9.58 Million USD | -173.172% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -99.481% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -99.481% |
| SCYNEXIS, Inc. | 51.84 Million USD | 49.505% |
| Safety Shot Inc | 12.1 Million USD | -116.197% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -753.02% |
| Procaps Group, S.A. | 199.47 Million USD | 86.875% |
| Theratechnologies Inc. | 72.75 Million USD | 64.016% |
| Harrow Health, Inc. | 89.97 Million USD | 70.902% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -177.163% |
| Biofrontera Inc. | 39.95 Million USD | 34.481% |
| DURECT Corporation | 43.71 Million USD | 40.11% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 95.051% |
| Cronos Group Inc. | 96.7 Million USD | 72.928% |
| OptiNose, Inc. | 85.1 Million USD | 69.236% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 88.721% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | 33.132% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 373.829% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 91.666% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -169.05% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | 39.172% |
| Radius Health, Inc. | 265.92 Million USD | 90.155% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -89.141% |
| ProPhase Labs, Inc. | 37.85 Million USD | 30.834% |
| Phibro Animal Health Corporation | 260.29 Million USD | 89.942% |
| Procaps Group S.A. | 187.24 Million USD | 86.018% |
| Alvotech | 285.43 Million USD | 90.828% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -166.471% |
| Viatris Inc. | 5.96 Billion USD | 99.561% |
| Rockwell Medical, Inc. | 15.37 Million USD | -70.293% |
| Aytu BioPharma, Inc. | 59.84 Million USD | 56.249% |
| SIGA Technologies, Inc. | 22.04 Million USD | -18.771% |
| Tilray Brands, Inc. | 251.35 Million USD | 89.584% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | 46.611% |
| Shineco, Inc. | 17.94 Million USD | -45.87% |
| PetIQ, Inc. | 192.72 Million USD | 86.415% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -555.973% |
| Incannex Healthcare Limited | 30.05 Million USD | 12.885% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 98.36% |
| Alimera Sciences, Inc. | 62.64 Million USD | 58.205% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -3333.582% |
| Assertio Holdings, Inc. | 368.58 Million USD | 92.897% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -344.83% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -47.013% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -23.675% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -24.421% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 84.13% |
| Hempacco Co., Inc. | 7.59 Million USD | -244.645% |
| Talphera, Inc. | 11.99 Million USD | -118.282% |
| Alvotech | 285.43 Million USD | 90.828% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 81.394% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 92.409% |
| Currenc Group, Inc. | 24 Million USD | -9.077% |
| Kamada Ltd. | 45.42 Million USD | 42.366% |
| Indivior PLC | 911 Million USD | 97.126% |
| Evoke Pharma, Inc. | 12.4 Million USD | -110.971% |
| Flora Growth Corp. | 10.57 Million USD | -147.479% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -24.421% |
| Evolus, Inc. | 189.75 Million USD | 86.203% |
| HUTCHMED (China) Limited | 436.23 Million USD | 93.998% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 83.014% |
| Akanda Corp. | 3.48 Million USD | -651.564% |